Health Prospective and Education, Conseil Général de l'Isère, Grenoble, France.
Free testing center for sexually transmitted infections (CEGIDD), Conseil Général de l'Isère, Grenoble, France.
Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1483-1489. doi: 10.1007/s10096-017-2957-0. Epub 2017 Mar 11.
In France, hepatitis B (HB) vaccine has been offered to all infants since 1994, and was proposed to all children aged 11 years from 1994 to 1998. Nevertheless, HB vaccine hesitancy may result in low vaccination coverage in present-day at-risk adults. We aimed to determine HB vaccination coverage in adults attending a free testing center for sexually transmitted infections (STI). As part of routine care, three classes of data were anonymously collected from attendees over a 3-month period: results of HB serologic tests; date and number of past anti-hepatitis B virus (HBV) immunization(s) (if any) according to health records; and the risk of STI and blood-transmitted infections (BTI). The study included 735 participants (age 27.9 ± 9.2; 59.9% men). According to available health records (341 participants), 56.6% had received at least three and 67.2% at least one vaccine injection(s); 57.7% had received their last injection between 1994 and 1998, reflecting the strong vaccine policy during these years. Serologic testing (in 705 participants) showed evidence of a past or active HBV infection for 33 participants; of the remaining patients, 55.3% had anti-HBs antibody titers ≥10 IU/L. This rate was not higher in participants considered at risk for STI/BTI. Of the participants who received their last vaccine injection more than 15 years previously, 90.5% had anti-HBs antibody concentrations ≥10 and 60.3% ≥100 IU/mL. HB vaccination coverage is low in this population. Most of the vaccinated participants were immunized between 1994 and 1998, suggesting a failure of catch-up immunization of adolescents and at-risk adults. Long-term seroprotection persisted among vaccinated participants.
在法国,自 1994 年以来,乙型肝炎(HB)疫苗已面向所有婴儿提供,并于 1994 年至 1998 年期间向所有 11 岁儿童提供。然而,HB 疫苗犹豫可能导致当前高危成年人的疫苗接种率低。我们旨在确定在参加性传播感染(STI)免费检测中心的成年人中的 HB 疫苗接种率。作为常规护理的一部分,在 3 个月的时间内,从参与者那里匿名收集了三类数据:HB 血清学检测结果;根据健康记录,过去(如果有)接受过抗乙型肝炎病毒(HBV)免疫接种的日期和次数;以及性传播感染(STI)和血液传播感染(BTI)的风险。该研究包括 735 名参与者(年龄 27.9±9.2;59.9%为男性)。根据可用的健康记录(341 名参与者),56.6%至少接受了三剂,67.2%至少接受了一剂疫苗;57.7%的最后一剂疫苗接种是在 1994 年至 1998 年之间,反映了这些年期间的强大疫苗政策。血清学检测(在 705 名参与者中)显示 33 名参与者存在过去或现有的 HBV 感染证据;在其余患者中,55.3%的抗-HBs 抗体滴度≥10 IU/L。考虑到 STI/BTI 风险的参与者中,这一比例没有更高。在过去 15 年以上接受最后一剂疫苗接种的参与者中,90.5%的抗-HBs 抗体浓度≥10,60.3%的浓度≥100 IU/mL。在该人群中,HB 疫苗接种率较低。大多数接受过疫苗接种的参与者是在 1994 年至 1998 年之间接种的,这表明青少年和高危成年人的补种免疫接种失败。接种疫苗的参与者中持续存在长期的血清保护。